Featured Articles

  1. Completed Clinical Trials Continued To Climb In 2024 6/19/2025

    Data collected in this report reflects a shift toward sustained growth, reflecting rapid advancement in therapeutic areas such as oncology, autoimmune/inflammation, and central nervous system studies.

  2. Data Key In Addressing Patient Recruitment Challenges 6/19/2025

    Explore how a Phase II trial for extensive-stage and previously treated small cell lung cancer overcame recruitment challenges with a data-driven solution designed to surface protocol-matched patients.

  3. Zeroing In On The Right Patients With RWD & Proprietary Data 4/28/2025

    Complex I/E criteria? Seeking broad demographic representation? Don’t know where to find eligible patients? No problem! See how comprehensive data and a connected ecosystem combine to revamp recruitment.

  4. The Future Of Patient Recruitment: Leveraging RWD For Precision 4/25/2025

    To combat the costly challenges of patient recruitment and keep trials on track, sponsors can leverage real-world data.

  5. Unlocking The Potential of RWD In Clinical Trial Recruitment 4/25/2025

    Explore how real-world data (RWD) is transforming recruitment strategies and leveraging technologies such as AI and machine learning.

  6. Overcoming Complex Patient Recruitment Challenges With Data 4/15/2025

    Overcome roadblocks to recruiting patients for rare disease clinical trials with RWD and RWE, including lack of diagnosis and stringent I/E criteria, geographic dispersion, and high dropout rates.

  7. Global Trial Disclosure Landscape Grows Increasingly Complex 4/15/2025

    The industry is witnessing a global trend toward increased transparency and more stringent enforcement of clinical trial reporting requirements. However mechanisms and penalties differ significantly across regions and countries.

  8. Faster Trial Planning and Site Selection 4/15/2025

    Address the challenges of identifying the most suitable trial sites and investigators while optimizing feasibility planning, reducing screen failure rates, and improving patient retention.

  9. A Dip In NAS Launches Annual Review 2025 Supplement 4/15/2025

    Even though new active substance (NAS) launches declined 11% in 2024, this still represented the fourth-highest total of newcomers to the pharma runway recorded and predictions remain good for 2025.

  10. Life Sciences Companies Talk Past, Present, And Future At JPM 3/21/2025

    The 43rd annual J.P. Morgan Healthcare Conference featured presentations from a host of large, medium, and small-cap life sciences companies that discussed past performance and future outlooks.